CO2019007188A2 - Secuelas de lesión pulmonar inducida por baipás cardiopulmonar - Google Patents
Secuelas de lesión pulmonar inducida por baipás cardiopulmonarInfo
- Publication number
- CO2019007188A2 CO2019007188A2 CONC2019/0007188A CO2019007188A CO2019007188A2 CO 2019007188 A2 CO2019007188 A2 CO 2019007188A2 CO 2019007188 A CO2019007188 A CO 2019007188A CO 2019007188 A2 CO2019007188 A2 CO 2019007188A2
- Authority
- CO
- Colombia
- Prior art keywords
- cardiopulmonary
- sequelae
- injury induced
- pulmonary injury
- pulmonary
- Prior art date
Links
- 208000004852 Lung Injury Diseases 0.000 title abstract 2
- 230000002612 cardiopulmonary effect Effects 0.000 title abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010018910 Haemolysis Diseases 0.000 abstract 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 abstract 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 abstract 1
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 abstract 1
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 abstract 1
- 229960002173 citrulline Drugs 0.000 abstract 1
- 235000013477 citrulline Nutrition 0.000 abstract 1
- 239000000539 dimer Substances 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 230000008588 hemolysis Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Lubricants (AREA)
- Amplifiers (AREA)
- Medicinal Preparation (AREA)
Abstract
Un método para administrar citrulina a un paciente durante la cirugía sin filtración de la hemólisis para reducir el desacoplamiento del dímero de la enzima eNOS que conduce a lesión pulmonar inducida por baipás cardiopulmonar.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662439772P | 2016-12-28 | 2016-12-28 | |
PCT/US2017/068698 WO2018125999A1 (en) | 2016-12-28 | 2017-12-28 | Sequelae of cardiopulmonary bypass-induced pulmonary injury |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019007188A2 true CO2019007188A2 (es) | 2019-07-31 |
Family
ID=62710740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0007188A CO2019007188A2 (es) | 2016-12-28 | 2019-07-03 | Secuelas de lesión pulmonar inducida por baipás cardiopulmonar |
Country Status (14)
Country | Link |
---|---|
US (1) | US10265286B2 (es) |
EP (1) | EP3506892B1 (es) |
JP (1) | JP7236384B2 (es) |
KR (1) | KR102327069B1 (es) |
CN (1) | CN109922799B (es) |
AR (1) | AR110663A1 (es) |
AU (2) | AU2017388398A1 (es) |
BR (1) | BR112019007245A2 (es) |
CA (1) | CA3048432A1 (es) |
CO (1) | CO2019007188A2 (es) |
IL (2) | IL300046A (es) |
MX (1) | MX2019005670A (es) |
RU (1) | RU2762593C2 (es) |
WO (1) | WO2018125999A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230404956A1 (en) * | 2022-06-21 | 2023-12-21 | Asklepion Pharmaceuticals Llc | Therapeutic window for citrulline therapy |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9486429B2 (en) | 1999-06-01 | 2016-11-08 | Vanderbilt University | Therapeutic methods employing nitric oxide precursors |
US6346382B1 (en) | 1999-06-01 | 2002-02-12 | Vanderbilt University | Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto |
CN101083589B (zh) | 2007-07-13 | 2010-08-11 | 华为技术有限公司 | 无源光网络中的终端检测认证方法、装置及操作管理系统 |
KR20100135729A (ko) | 2008-01-31 | 2010-12-27 | 반더빌트유니버시티 | 폐의 용태에 따른 치료 방법 |
WO2017004233A1 (en) | 2015-06-29 | 2017-01-05 | Vanderbilt University | Intravenous administration of citrulline during surgery |
-
2017
- 2017-12-22 US US15/853,248 patent/US10265286B2/en active Active
- 2017-12-27 AR ARP170103691A patent/AR110663A1/es unknown
- 2017-12-28 EP EP17887010.1A patent/EP3506892B1/en active Active
- 2017-12-28 AU AU2017388398A patent/AU2017388398A1/en not_active Abandoned
- 2017-12-28 KR KR1020197015117A patent/KR102327069B1/ko active IP Right Grant
- 2017-12-28 CA CA3048432A patent/CA3048432A1/en active Pending
- 2017-12-28 RU RU2019123427A patent/RU2762593C2/ru active
- 2017-12-28 BR BR112019007245A patent/BR112019007245A2/pt active Search and Examination
- 2017-12-28 IL IL300046A patent/IL300046A/en unknown
- 2017-12-28 JP JP2019534922A patent/JP7236384B2/ja active Active
- 2017-12-28 CN CN201780069489.XA patent/CN109922799B/zh active Active
- 2017-12-28 WO PCT/US2017/068698 patent/WO2018125999A1/en active Application Filing
- 2017-12-28 MX MX2019005670A patent/MX2019005670A/es unknown
-
2019
- 2019-06-27 IL IL267707A patent/IL267707A/en unknown
- 2019-07-03 CO CONC2019/0007188A patent/CO2019007188A2/es unknown
-
2024
- 2024-02-15 AU AU2024200984A patent/AU2024200984A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR112019007245A2 (pt) | 2019-07-02 |
MX2019005670A (es) | 2019-08-12 |
IL300046A (en) | 2023-03-01 |
RU2019123427A (ru) | 2021-01-29 |
CN109922799A (zh) | 2019-06-21 |
CA3048432A1 (en) | 2018-07-05 |
KR20190101363A (ko) | 2019-08-30 |
CN109922799B (zh) | 2021-11-16 |
US20180214403A1 (en) | 2018-08-02 |
RU2019123427A3 (es) | 2021-05-20 |
EP3506892A4 (en) | 2020-05-06 |
EP3506892A1 (en) | 2019-07-10 |
IL267707A (en) | 2019-08-29 |
RU2762593C2 (ru) | 2021-12-21 |
WO2018125999A1 (en) | 2018-07-05 |
KR102327069B1 (ko) | 2021-11-16 |
AR110663A1 (es) | 2019-04-17 |
JP7236384B2 (ja) | 2023-03-09 |
US10265286B2 (en) | 2019-04-23 |
AU2024200984A1 (en) | 2024-03-07 |
AU2017388398A1 (en) | 2019-05-23 |
JP2020503326A (ja) | 2020-01-30 |
EP3506892B1 (en) | 2024-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2016002517A1 (es) | Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica. | |
EA201790398A1 (ru) | Способы лечения заболевания печени | |
EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
EA201692436A1 (ru) | Медицинское применение | |
BR112017008659A2 (pt) | ?métodos e compostos de agonista de gip? | |
BR112016018548A2 (pt) | composto, ácido, medicamento, e, uso de um composto. | |
SV2018005682A (es) | Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana | |
CY1126036T1 (el) | Δοσολογικο σχημα σακουμπιτριλης-βαλσαρτανης για τη θεραπευτικη αντιμετωπιση της καρδιακης ανεπαρκειας | |
BR112016025470A2 (pt) | ?hdl terapêutico? | |
MX2016010651A (es) | Vacunas de virus aviar que son estables en liquido. | |
CY1124759T1 (el) | Μεθοδοι για τη θεραπεια της οξειας νεφρικης βλαβης | |
CL2019001996A1 (es) | Usos terapéuticos de un polvo de insectos. | |
DOP2017000098A (es) | Compuesto heterocíclico | |
EA201691860A1 (ru) | Пептидный медикамент в виде сухого порошка | |
CL2016002779A1 (es) | Composición para el cuidado de la piel | |
ECSP16096831A (es) | Derivados de naftiridinadiona | |
EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
CO2019007188A2 (es) | Secuelas de lesión pulmonar inducida por baipás cardiopulmonar | |
CY1123243T1 (el) | Ενωση προερχομενη απο πυραζολινη και η χρηση τησσε ενα θεραπευτικο σχημα εβδομαδιαιας δοσολογησης εναντια στην φλεγμονη και τον πονο που προερχονται απο την εκφυλιστικη ασθενεια των αρθρωσεων στα θηλαστικα | |
EA201891008A3 (ru) | Лечение симптомов, связанных с андроген-депривационной терапией | |
EA201692371A1 (ru) | 1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений | |
EA201501130A1 (ru) | Офтальмологическая фармацевтическая композиция | |
EA201691218A1 (ru) | Агонисты a1-аденозиновых рецепторов в качестве лекарственного средства для лечения заболеваний почек | |
CY1124271T1 (el) | Παραγοντας αγωγης της δερματομυκωσης που περιλαμβανει κιτρικο τρικαλιο | |
CY1121388T1 (el) | Παραγωγα βενζυλυδροξειδιου, παρασκευη αυτων και θεραπευτικη χρηση αυτων |